Athina Angelopoulou

Dr. Athina Angelopoulou

Metabolomics and Systems Biology, FORTH Institute of Chemical Engineering Sciences, Pátrai, Greece
+1
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in ACS Omega
Verified
Journal Article
Open access
AAAthina Angelopoulou
Athina Angelopoulou
AKArgiris Kolokithas-Ntoukas
Argiris Kolokithas-Ntoukas
CFChristos Fytas
Christos Fytas
KAKonstantinos Avgoustakis
Konstantinos Avgoustakis
This study concerns the development of folic acid (FA)-functionalized iron oxide condensed colloidal magnetic clusters for a more selective delivery of doxorubicin (DOX) to tumor cancer cells overexpressing the folate receptor. Alginate-coated condensed magnetic nanoparticles (co-MIONs) were synthesized via an alkaline precipitation method of an iron precursor in the presence of sodium alginate. Poly(ethylene glycol) (OH-PEG-NH2) was conjugated to the carboxylic acid end group of alginate and folic acid (FA) was conjugated to the hydroxyl terminal group of PEG to produce folate-functionalized, pegylated co-MIONS (Mag-Alg-PEG-FA). The physicochemical properties of nanoparticles were fully characterized. DOX was loaded on the nanoparticles, and the cellular uptake and anticancer efficacy of the nanoparticles were examined in cancer cell lines expressing and not expressing the folate receptor. The biocompatibility of the carrier (blank nanoparticles) was also evaluated by cytocompatibility and hemocompatibility experiments. The nanoparticles exhibited sustained DOX release in aqueous buffers and biorelevant media, which was responsive to pH and external alternating current magnetic fields. The effect of the magnetic field on DOX percentage release appeared to be independent of the timing (onset time) of magnetic field application, providing flexibility to the magnetic control of drug release from the nanoparticles. The blank nanoparticles were not cytotoxic and did not cause hemolysis. The DOX-loaded and FA-functionalized nanoparticles exhibited increased uptake and caused increased apoptosis and cytotoxicity against the MDA-MB-231 cell line, expressing the folate receptor, compared to the MCF-7 cell line, not expressing the folate receptor. The application of a 0.5 T magnetic field during incubation of the nanoparticles with the cancer cells increased the cellular uptake and cytotoxicity of the nanoparticles. The obtained results indicate the potential of the folate-functionalized, pegylated co-MIONS for a more efficacious DOX delivery to cancer cells of solid tumors.

1 June 2015 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
AAAthina Angelopoulou
Athina Angelopoulou
EVE. Voulgari
E. Voulgari
EDE.K. Diamanti
E.K. Diamanti
Dimitrios GournisDimitrios Gournis
Dimitrios Gournis
Konstantinos AvgoustakisKonstantinos Avgoustakis
Konstantinos Avgoustakis

23 June 2020 in Environmental Research
Verified
Journal Article
Closed access
AAAthina Angelopoulou
Athina Angelopoulou
NANikos Alexandris
Nikos Alexandris
EKEvangelia Konstantinou
Evangelia Konstantinou
KMKonstantinos Mesiakaris
Konstantinos Mesiakaris
CZCharilaos Zanidis
Charilaos Zanidis
Konstantinos PoulasKonstantinos Poulas
Konstantinos Poulas

22 May 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
Konstantinos FarsalinosKonstantinos Farsalinos
Konstantinos Farsalinos
AAAthina Angelopoulou
Athina Angelopoulou
NANikos Alexandris
Nikos Alexandris
KPKonstantinos Poulas
Konstantinos Poulas

1 January 2008 in Journal of Non-Crystalline Solids
Verified
Journal Article
Closed access
AAAthina Angelopoulou
Athina Angelopoulou
Valérie MontouilloutValérie Montouillout
Valérie Montouillout
DMD. Massiot
D. Massiot
GKG. Kordas
G. Kordas

26 January 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Konstantinos AvgoustakisKonstantinos Avgoustakis
Konstantinos Avgoustakis
AAAthina Angelopoulou
Athina Angelopoulou
Solid tumors are composed of a highly complex and heterogenic microenvironment, with increasing metabolic status. This environment plays a crucial role in the clinical therapeutic outcome of conventional treatments and innovative antitumor nanomedicines. Scientists have devoted great efforts to conquering the challenges of the tumor microenvironment (TME), in respect of effective drug accumulation and activity at the tumor site. The main focus is to overcome the obstacles of abnormal vasculature, dense stroma, extracellular matrix, hypoxia, and pH gradient acidosis. In this endeavor, nanomedicines that are targeting distinct features of TME have flourished; these aim to increase site specificity and achieve deep tumor penetration. Recently, research efforts have focused on the immune reprograming of TME in order to promote suppression of cancer stem cells and prevention of metastasis. Thereby, several nanomedicine therapeutics which have shown promise in preclinical studies have entered clinical trials or are already in clinical practice. Various novel strategies were employed in preclinical studies and clinical trials. Among them, nanomedicines based on biomaterials show great promise in improving the therapeutic efficacy, reducing side effects, and promoting synergistic activity for TME responsive targeting. In this review, we focused on the targeting mechanisms of nanomedicines in response to the microenvironment of solid tumors. We describe responsive nanomedicines which take advantage of biomaterials’ properties to exploit the features of TME or overcome the obstacles posed by TME. The development of such systems has significantly advanced the application of biomaterials in combinational therapies and in immunotherapies for improved anticancer effectiveness.